Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention

Perkan, Andrea; Vitrella, Giancarlo; Barbati, Giulia; Monte, Ariella De; D’Agata, Bianca; Merlo, Marco; Giannini, Francesco; Grazia, Erica Della; Rakar, Serena; Salvi, Alessandro; Igidbashian, D.; Morgera, T; Zalukar, Walter; Sinagra, Gianfranco

doi:10.2459/jcm.0b013e32834eec7a

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 In the observation by Perkan et al, abciximab treatment was associated with a lower in-hospital rate and 30-day mortality rate, and a lower incidence of death and reinfarction at 30 days in diabetic patients undergoing primary percutaneous coronary intervention due to acute myocardial infarction. 50 Anticoagulants inhibit the coagulation cascade that happens after the initial platelet aggregation. They are used in the treatment and prophylaxis of venous thrombosis.…”

Section: Treatment and Prophylaxismentioning

confidence: 99%

The pathogenesis and available prevention options in patients with diabetic thrombophilia

Kwiatkowski¹,

Halupczok-Żyła²,

Bolanowski³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

Diabetes mellitus (DM), a growing health problem itself, is accompanied by an increased risk of cardiovascular and thrombotic complications. The imbalance between coagulation and fibrinolysis processes observed in patients with diabetes may be defined as diabetic thrombophilia. Several mechanisms are involved in the hypercoagulability state in diabetics, including endothelial cell damage, altered platelet structure and function, increased microparticle formation, different structure of fibrin clots, disturbances in the activity of coagulation factors, fluctuations in the concentrations of fibrinolysis activators and inhibitors, and qualitative changes of proteins due to glycation and oxidation processes. These all are the reasons why DM is the most common cause of acquired thrombophilia. Moreover, diabetes changes the efficacy of certain medications. Results of various trials seem to suggest that thrombolytic drugs are less effective in patients suffering from this disease. The impact of DM on the effectiveness of treatment with acetylsalicylic acid (ASA) remains unclear. Awareness of thrombotic complications in diabetic patients may enable earlier diagnosis and proper therapy.

show abstract

Section: Treatment and Prophylaxismentioning

confidence: 99%